[Myocardial regeneration therapy for @entity712 : XXXX enhances the effect of cellular cardiomyoplasty].

@entity1 @entity82 @entity712 @entity2295 @entity15794 @entity35 @entity583
BACKGROUND: We hypothesized that transfection of the gene for @entity1 @entity15794 (hHGF) combined with cellular cardiomyoplasty might regenerate the impaired myocardium. METHODS AND RESULTS: We used a ligation model of proximal left anterior descending coronary artery of Lewis @entity35 . Two weeks after left anterior descending coronary artery ligation, three different treatments were conducted; 1) neonatal @entity35 cardiomyocytes group(10(6) cells, T group, n = 11), 2) HVJ-liposomes bearing the hHGF gene group (H group, n = 10), and 3) combined(T-H group, n = 10). The injection site was the scar area of @entity583 . For control, culture medium was injected (C group, n = 13). Echocardiography demonstrated that cardiac performance was significantly ameliorated in the T-H group 4 and 8 weeks after injection. Contrast echocardiography also showed a marked increase in myocardial perfusion in the T-H group but not in the other groups. In the T-H group, @entity2295 and a marked @entity82 were observed histologically. In an immunohistochemical study, strong staining for beta 1-integrin, alpha- and beta-dystroglycan were found principally in the basement membrane of myocytes in the T-H group 8 weeks after transplantation, although there was weak immunoreactivity in the T group. CONCLUSIONS: hHGF gene transfection enhanced the cellular cardiomyoplasty possibly by stimulating angiogenesis, restoring the impaired extracellular matrix, and promoting the integration of the dissociated grafted myocytes. The combined effects might have lead to the improved cardiac performance. Thus, combined therapy may be a promising strategy for the treatment of @entity712 caused by @entity583 .
